Equivalent Medications to Ubrelvy (Ubrogepant)
The direct equivalents to Ubrelvy are rimegepant (Nurtec ODT) and zavegepant (Zavzpret)—both are CGRP receptor antagonists (gepants) in the same drug class with similar efficacy for acute migraine treatment. 1
Same Drug Class (CGRP Antagonists-Gepants)
The most directly equivalent medications are other gepants:
- Rimegepant (Nurtec ODT) - orally disintegrating tablet
- Zavegepant (Zavzpret) - intranasal spray
These three gepants have comparable efficacy profiles. According to the 2025 American College of Physicians guidelines, all three are grouped together as treatment options for moderate to severe acute episodic migraine in patients who don't respond to or can't tolerate combination therapy with a triptan plus NSAID or acetaminophen 1.
Network meta-analyses show no statistically significant differences in efficacy between ubrogepant, rimegepant, and lasmiditan for pain freedom or pain relief at 2 hours 2, 3, 4. The number needed to treat (NNT) for pain freedom at 2 hours is 12 for ubrogepant, 9 for rimegepant, and 11 for zavegepant—all clinically similar 5.
Key Distinction Among Gepants
Rimegepant is the most cost-effective gepant option and should be your first choice if prescribing within this class 6. It was both less costly and more effective than zavegepant in cost-effectiveness analyses, with an incremental cost-effectiveness ratio of $93,700 per QALY compared to ubrogepant 6.
Alternative Acute Migraine Treatments (Different Mechanisms)
If you need alternatives outside the gepant class:
First-Line Options (Try These First)
- Triptans + NSAID combination - This is actually superior to gepants for pain freedom and relief at 2 hours 7. Specific triptans include:
- Sumatriptan, rizatriptan, eletriptan, almotriptan, frovatriptan, naratriptan, or zolmitriptan
- Combined with ibuprofen, naproxen, diclofenac, aspirin, or celecoxib
- Or combined with acetaminophen if NSAIDs contraindicated 1
Most triptans show higher odds ratios for pain freedom compared to ubrogepant (OR range 1.54-3.05) 7. The gepants are specifically reserved for patients who fail triptan combination therapy 1.
Second-Line Options (If Triptans Fail)
Lasmiditan (Reyvow) - A 5-HT1F receptor agonist (ditan class)
Dihydroergotamine (DHE) - Ergot alkaloid
Clinical Algorithm for Selecting Alternatives
Start with adequate-dose NSAID or acetaminophen - Ensure proper dosing before escalating 1
If inadequate response, add a triptan to the NSAID/acetaminophen (this is more effective than gepants) 1
If triptan combination fails or contraindicated, then consider gepants:
If all gepants fail, consider lasmiditan 1
Never use opioids or butalbital 1
Important Caveats
- Gepants are NOT first-line therapy—they're specifically for patients who fail or can't tolerate triptan combination therapy 1
- Medication overuse headache threshold: ≥10 days/month for triptans, ≥15 days/month for NSAIDs 1
- Cardiovascular advantage: Gepants and lasmiditan lack the cardiovascular risks associated with triptans, making them valuable alternatives in patients with cardiovascular contraindications 7
- Pregnancy: Discuss risks with patients of childbearing potential; gepants have limited safety data in pregnancy 1, 8
- Drug interactions with ubrogepant: Avoid strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole); dose adjustment needed with moderate inhibitors like verapamil 8
If a patient isn't responding adequately to ubrogepant, switching to another gepant (rimegepant or zavegepant) may not provide substantially better results—instead, consider whether they've truly failed optimized triptan combination therapy first, or move to lasmiditan if all other options exhausted 2, 3.